Identification of a novel inflammatory-related gene signature to evaluate the prognosis of gastric cancer patients
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a new three-gene signature to predict gastric cancer (GC) prognosis. This inflammatory-related biomarker model helps personalize treatment for GC patients.
Area Of Science
- Oncology
- Cancer Genomics
- Inflammation and Cancer
Background
- Gastric cancer (GC) is a complex and aggressive malignancy with variable prognosis.
- Inflammation is a key factor in GC development and progression, impacting patient outcomes.
- Identifying reliable prognostic biomarkers for GC is crucial for effective treatment strategies.
Purpose Of The Study
- To develop and validate an inflammatory-related gene signature for predicting gastric cancer patient prognosis.
- To assess the signature's ability to stratify patients and guide personalized treatment decisions.
Main Methods
- Utilized Gene Expression Omnibus (GEO) datasets (GSE66229 and GSE26253) for GC patients.
- Constructed a prognostic model using least absolute shrinkage and selection operator (LASSO) Cox regression with inflammatory genes.
- Validated the model through univariate/multivariate Cox analyses, nomogram establishment, and decision curve analysis.
Main Results
- A three-gene prognostic signature (MRPS17, GUF1, PDK4) was developed, identifying high-risk patients with poorer prognoses.
- The risk score independently predicted GC prognosis, outperforming traditional staging.
- Identified distinct inflammatory subtypes and linked the risk score to differential drug sensitivity.
Conclusions
- A novel three-gene prognostic signature for gastric cancer was established.
- This signature aids in predicting prognosis and personalizing treatment for GC patients.
- The findings highlight the role of inflammation in GC and its potential for therapeutic targeting.

